NABI BIOPHARMACEUTICALS : AVEO

drenan

17 février 2011 •20:57

Key Developments: AVEO Pharmaceuticals Inc (AVEO.O)

Related Topics:
* Stocks
* Stock Screener
* Healthcare
* Biotechnology / Medical Research

* Overview
* News
* Key Developments
* People
* Charts
* Financials
* Options
* Analysts
* Research

AVEO.O on Consolidated Issue listed on NASDAQ Global Market

14.20USD
2:38pm EST
Price Change (% chg)

$0.32 (+2.31%)
Prev Close
$13.88
Open
$16.00
Day's High
$16.00
Day's Low
$14.01
Volume
514,340
Avg. Vol
158,260
52-wk High
$17.93
52-wk Low
$6.01

Research a stock:
Latest Key Developments
Astellas Pharma Inc And AVEO Pharmaceuticals Enter Into Worldwide Agreement
Wednesday, 16 Feb 2011 04:02pm EST

Astellas Pharma Inc. and AVEO Pharmaceuticals, Inc. announced they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, Under the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in research and development funding. AVEO is also eligible to receive approximately $1.3 billion in potential milestones comprised of $575 million in clinical and regulatory milestones, including $90 million in connection with the regulatory filings and market approval of tivozanib in RCC, as well as more than $780 million in commercial milestones. AVEO will lead commercialization of tivozanib in North America and Astellas will lead commercialization of tivozanib in the European Union (EU). The companies will share equally all North American and EU development and commercialization costs and profits for tivozanib. Outside of North America and EU, Astellas will be responsible for the development and commercialization costs of tivozanib and will be obligated to pay AVEO a royalty on sales in those territories. Pursuant to the terms of a licensing agreement between Kyowa Hakko Kirin and AVEO, Kyowa Hakko Kirin retains the rights to develop and commercialize tivozanib in Asia. AVEO will be responsible for the manufacturing of tivozanib.

drenan

18 février 2011 •15:53

inutile d'insister ... j'attendais un gap

Profil supprimé

01 avril 2011 •21:15

in 13,2$

Parce que le graphe me semble prometteur, mais pas d'info imminente à priori (Top-line data from TIVO-1 evaluating tivozanib in RCC = Mid-2011E).

Profil supprimé

09 mai 2011 •21:34

Les résultats T1 ont été bien accueillis mais je sors car il semble que les données pour Tivo-1 seront plus tardives que prévues (Q4 ?)

Profil supprimé

19 mai 2011 •23:30

RAPPEL : source Fiercebiotech - Avril 2011
j'avoue qu'elle est à surveiller cette petite...

David, je ne comprends pas pourquoi tu penses que les résus pour Tivozanib vont avoir du retard ; dans l'article de Fiercebiotech, ils disent : "Aveo plans to report results of the trial in mid-2011"

>>>

Tivozanib - 10 promising late-stage cancer drugs

April 4, 2011 — 9:35am ET | By Ryan McBride

Tuan Ha-Ngoc, the president and CEO of Aveo Pharmaceuticals ($AVEO), is leading a very smart charge to advance tivozanib to the market for kidney cancers called advanced renal cell carcinoma (RCC).
In June 2010, the company showed results from a Phase II study of a the drug--a potent blocker of all three vascular endothelial growth factor (VEGF) receptors, which play a role in the formation of blood vessels that feed tumors--that patients taking the drug on average lived without their cancer getting worse for 11.8 months. That same key indicator of effectiveness was nearly 14.8 months among patients with a clear cell form of RCC who had prior surgeries to remove at least part of their kidneys.
In the company's 517-patient Phase III trial comparing tivozanib head-to-head with Onyx Pharmaceuticals' and Bayer's Nexavar, patients who enter the study must have a clear cell form of the disease and previously have had the surgery to be eligible (the types of patients who did really well in the Phase II study). Aveo plans to report results of the trial in mid-2011. It's also worth keeping an eye on Pfizer's similar drug, axitinib, for which the drug giant plans to submit in 2011 applications for U.S. and European regulatory approvals as a treatment for patients with kidney cancer.
Aveo is sharing equally North American and European development costs and profits related to tivozanib with Japan's Astellas Pharma. Kyowa Hakko Kirin has rights to develop and commercialize the drug in Asia.

Profil supprimé

20 mai 2011 •02:01

David n'y est pour rien, laissons le profiter du repos des braves si César lui permet. C'est une demi-erreur de ma part.

Demi car dans les commentaires des résultats Q1, il était dit :"Based upon the current event-rate, we do not anticipate top-line TIVO-1 data until at least the fourth quarter of this year." Je comprends que les résultats phase 3 arriveront au Q4.

Mais Aveo va bien fournir des données (plus complètes ?) sur le TIVO-1 (pour RCC) début juin à l'Asco sur phase II.

Je n'en attends pas un gros impact dans la mesure où on sait déjà que la phase 2 a été réussie. Mais une belle action à garder en mémoire.

Profil supprimé

15 juin 2011 •01:37

Aveo vient de lancer une AK, dont les conditions ne sont pas encore bien éclaircies (peut-être 5M d'actions, à quel cours ?).

Assez surprenant dans la mesure où Aveo dispose d'un gros matelas de cash bien moelleux. Peut-être encore un peu tôt pour y revenir avant leur phase 3 au Q4.

Profil supprimé

15 juin 2011 •20:56

Ils en reprennent pour 100M$ de cash, à un cours de 17,5$.

Aveo Pharma plans to sell 5.8M shares of stock, raising $101M before expenses and discounts
15 juin 2011
Associated Press Newswires

CAMBRIDGE, Mass. (AP) - Aveo Pharmaceuticals Inc. said Wednesday that it will sell 5.8 million shares of stock for $17.50 per share.

The company said it expects to raise $100.6 million from the sale before discounts and expenses. Shares of Aveo have tripled in value over the past year as development of its lead drug candidate, the cancer treatment tivozanib, continued and the company entered a partnership with Japanese drugmaker Astellas.

The offering priced at a discount of 8.3 percent to Aveo's Tuesday closing price of $19.09. The stock fell $2.02, or 10.6 percent, to $17.07 in morning trading.

JPMorgan Securities and Jefferies & Co. are the joint book-running managers and underwriters for the offering, and Canaccord Genuity is the co-lead manager. The underwriters will have an option to buy up to 863,000 additional shares to cover any over allotments. The offering is expected to close on Monday.